Related Experiment Video
Updated: May 6, 2026
09:58
A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice
Published on: April 13, 2010
22.3K
Association between consistent omalizumab treatment and asthma control.
Marie-Hélène Lafeuille1, Jonathan Gravel, Jie Zhang
1Groupe d'analyse, Ltée, Montréal, Québec, Canada.
The Journal of Allergy and Clinical Immunology. in Practice
|November 16, 2013
Summary
Consistent omalizumab treatment significantly improves asthma control. Patients receiving uninterrupted therapy experienced fewer uncontrolled asthma events, emergency department visits, and hospitalizations.
Area of Science:
- Pulmonology
- Pharmacoeconomics
- Real-world evidence
Background:
- Omalizumab is indicated for moderate-to-severe allergic asthma.
- Inadequately controlled symptoms necessitate effective treatment strategies.
Purpose of the Study:
- To evaluate the association between consistent omalizumab treatment and asthma control.
- To assess the impact of treatment adherence on asthma-related outcomes.
Main Methods:
- Analysis of health insurance claims data (2002-2011).
- Inclusion of asthmatic patients with continuous insurance and omalizumab use.
- Assessment of treatment consistency over a 12-month landmark period.
- Multivariate time-varying Cox regressions to evaluate adjusted effects.
Main Results:
- Consistent omalizumab users (39%) had fewer uncontrolled asthma events (49% vs 54%).
- Consistent treatment reduced asthma-related emergency department visits by 51% and hospitalizations by 28%.
- Multivariate analyses confirmed reduced risks for exacerbations and healthcare utilization (HR 0.76).
Conclusions:
- Consistent omalizumab therapy is associated with improved asthma control.
- Adherence to omalizumab treatment significantly reduces emergency department visits and hospitalizations.
Keywords:
AdherenceAsthma controlAsthma treatmentClaims dataEDEmergency departmentEmergency department visitsHRHazard ratioHospitalizationsICSIDC-9Inhaled corticosteroidsInternational Classification of Diseases, Ninth RevisionLABALong-acting β(2)-agonistsOCSOmalizumabOral corticosteroidsPDCPersistenceProportion of days coveredResource utilizationSABAShort-acting β(2)-agonistsMore Related Videos
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
2.4K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.4K
01:20Asthma: Pathogenesis and Management
1.5K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.5K
01:13Asthma III: Clinical Manifestations
73
Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
73
01:19Antiasthma Drugs: Leukotriene Modifiers
2.2K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.2K
01:26Asthma-II: Pathophysiology and Classification
4.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.7K
01:30Asthma-IV: Nursing Management
4.0K
The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
First, in...
4.0K